Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda and Pavilion studies, showcasing the sustained efficacy and safety of Susvimo in treating two critical diabetic eye conditions: diabetic macular edema (DME) and diabetic retinopathy (DR). These conditions are among the leading causes of vision loss in […]
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential as a treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). This trial marks a significant milestone as datopotamab deruxtecan, a TROP2-directed antibody drug conjugate (ADC), showed a clinically meaningful improvement in overall survival (OS) compared to […]
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal valued at up to $1.05 billion. This acquisition is poised to strengthen the late-stage pipeline of Alexion, AstraZeneca Rare Disease, particularly bolstering its bone metabolism franchise through the addition of […]